Market Cap 486.51B
Revenue (ttm) 88.82B
Net Income (ttm) 14.07B
EPS (ttm) N/A
PE Ratio 19.51
Forward PE 18.63
Profit Margin 15.84%
Debt to Equity Ratio 0.50
Volume 7,785,500
Avg Vol 8,803,656
Day's Range N/A - N/A
Shares Out 2.41B
Stochastic %K 16%
Beta 0.36
Analysts Strong Sell
Price Target $205.25

Company Profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 732 524 0400
Website: www.jnj.com
Address:
One Johnson & Johnson Plaza, New Brunswick, United States
shalombt
shalombt Dec. 8 at 12:25 PM
$COST $JNJ $MA $JPM This is true for you too.
0 · Reply
seeitmarket
seeitmarket Dec. 8 at 7:27 AM
0 · Reply
andrewnyquist
andrewnyquist Dec. 8 at 6:15 AM
$JNJ Johnson & Johnson nearning important trend support area. It held the last 2 times. Will same pattern hold now? #IBDpartner @MarketSurge @InvestorsBusinessDaily
0 · Reply
RogerBarfield374
RogerBarfield374 Dec. 8 at 1:12 AM
💉 $JNJ CARVYKTI JUST TURNED MULTIPLE MYELOMA INTO A 30-MONTH VACATION One infusion and 80% of relapsed patients are still chilling treatment-free at 2.5 years—because apparently cancer didn’t get the memo that $JNJ rewrote the script. ⚡️ $JNJ drops updated Phase 3 bombshell: CARVYKTI keeps 80% of standard-risk patients progression-free for 30 months ⚡️ Works as early as second-line, single shot, no chemo, just vibes ⚡️ Already treated 9,000+ patients globally, real-world data backing the lab flex ⚡️ Earlier treatment = stronger immune comeback = longer cancer naps ⚡️ Big Pharma quietly turning “incurable” blood cancer into a manageable Tuesday
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 7 at 11:12 PM
Enter: $JNJ Calls Strike Price: $205 Expiry Date: JAN 02 2026 Buy in Price: $2.63 - $2.71 Sell Price: $4.39 Profit : +62% (Turn every $1 into $1.62) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
TalkMarkets
TalkMarkets Dec. 7 at 7:41 PM
Best #Dividend #Stocks For The #LongTerm - Sunday, Dec. 7 $CVX $JNJ $KO $MRK $O https://talkmarkets.com/content/real-estate--reits/best-dividend-stocks-for-the-long-term-sunday-dec-7?post=543058&userid=123969
0 · Reply
IrishFlyGirlQueenforever
IrishFlyGirlQueenforever Dec. 7 at 5:56 PM
$JNJ SLS Ven+aza has improved AML treatment by targeting BCL-2-dependent leukemic stem cells, but the prognosis is poor AML being heterogeneous and adaptable. Tho Ven can eliminate large portion of leukemic stem cells, others survive by relying on alternative anti-apoptotic proteins such as MCL-1 or BCL-XL, or by shifting their metabolic pathways. The bone marrow also provides protective shield on resistant cells. These surviving cells drive relapse, and resistance mechanisms limit long-term efficacy. GPS takes a different approach by activating the immune system to recognize and destroy cells expressing WT1 = leukemic stem cells. strategy is less vulnerable to the variability that undermines ven+aza. GPS induces immunologic memory, enabling long-term surveillance, reducing relapse risk. Unlike old regimens, GPS is used continuously maintaining immune pressure. GPS is disease-modifying rather than a temporary debulking therapy, offering a more durable solution to AML’s complexity
0 · Reply
USAStockmarket
USAStockmarket Dec. 7 at 2:59 PM
$LLY Eli Lilly $LLY, Pfizer $PFE and Johnson & Johnson $JNJ all secured spots on China’s 🇨🇳 first innovative drug catalog, which includes 19 medicines for conditions such as cancer and Alzheimer’s - Bloomberg
0 · Reply
TheUnmaker
TheUnmaker Dec. 7 at 4:31 AM
$BB $ISRG $JNJ $MDT https://blogs.blackberry.com/en/2024/01/revolutionizing-surgical-robotics-to-improve-patient-outcomes#:~:text=BlackBerry%C2%AE%20QNX%C2%AE%20is,with%20minimal%20impact%20on%20performance.
0 · Reply
TheUnmaker
TheUnmaker Dec. 7 at 4:19 AM
$BB $JNJ $MDT $ISRG https://www.surgicalroboticstechnology.com/company/qnx/
0 · Reply
Latest News on JNJ
16 Quality Stocks to Own for a Volatile Market

Dec 1, 2025, 1:23 PM EST - 6 days ago

16 Quality Stocks to Own for a Volatile Market

CSCO LLY XOM


2 Top Dividend Stocks to Buy and Hold

Nov 30, 2025, 4:05 AM EST - 8 days ago

2 Top Dividend Stocks to Buy and Hold

BMY


Best Dividend Aristocrats For December 2025

Nov 29, 2025, 8:02 AM EST - 9 days ago

Best Dividend Aristocrats For December 2025

ABBV ABT ADM ADP AFL ALB AMCR


Dogs Of The Dow Continue Outperforming Broader Market

Nov 29, 2025, 1:45 AM EST - 9 days ago

Dogs Of The Dow Continue Outperforming Broader Market

AMGN DIA MAGS SPY


Wasatch Global Value Fund Q3 2025 Performance Review

Nov 28, 2025, 7:50 AM EST - 10 days ago

Wasatch Global Value Fund Q3 2025 Performance Review

BABA CNC DOX NVDA


3 Superb Dividend Stocks to Hold for the Next 20 Years

Nov 27, 2025, 6:30 AM EST - 11 days ago

3 Superb Dividend Stocks to Hold for the Next 20 Years

KO O


1 Reason Why Shares of Johnson & Johnson Are Surging This Month

Nov 21, 2025, 12:43 PM EST - 16 days ago

1 Reason Why Shares of Johnson & Johnson Are Surging This Month


Why Johnson & Johnson's Share Price Is Popping This Month

Nov 19, 2025, 12:24 PM EST - 18 days ago

Why Johnson & Johnson's Share Price Is Popping This Month


Johnson & Johnson to Buy Halda Therapeutics For $3.05 Billion

Nov 17, 2025, 8:29 AM EST - 21 days ago

Johnson & Johnson to Buy Halda Therapeutics For $3.05 Billion


Halda Therapeutics Announces Acquisition by Johnson & Johnson

Nov 17, 2025, 8:15 AM EST - 21 days ago

Halda Therapeutics Announces Acquisition by Johnson & Johnson


Bristol Myers, J&J halt heart drug trial after interim review

Nov 14, 2025, 8:03 AM EST - 24 days ago

Bristol Myers, J&J halt heart drug trial after interim review

BMY


2 Strong Healthcare Stock Picks for Dividend Investors

Nov 13, 2025, 3:55 AM EST - 25 days ago

2 Strong Healthcare Stock Picks for Dividend Investors

ABBV


Johnson & Johnson: Dividends Don't Lie

Nov 7, 2025, 5:40 AM EST - 4 weeks ago

Johnson & Johnson: Dividends Don't Lie


Cramer's Mad Dash: Johnson & Johnson

Nov 6, 2025, 9:54 AM EST - 4 weeks ago

Cramer's Mad Dash: Johnson & Johnson


US FDA expands use of J&J's Caplyta as add-on depression drug

Nov 6, 2025, 7:34 AM EST - 4 weeks ago

US FDA expands use of J&J's Caplyta as add-on depression drug


Best Dividend Aristocrats For November 2025

Nov 1, 2025, 10:25 AM EDT - 5 weeks ago

Best Dividend Aristocrats For November 2025

ABBV ABT ADM ADP AMCR AOS ATO


Best Dividend Kings: October 2025

Oct 29, 2025, 5:11 AM EDT - 5 weeks ago

Best Dividend Kings: October 2025

ABBV ABM ABT ADM ADP AWR BDX


J&J Stock Can Fall

Oct 28, 2025, 9:25 AM EDT - 5 weeks ago

J&J Stock Can Fall


3 Healthcare Stocks to Buy Hand Over Fist in October

Oct 27, 2025, 10:45 AM EDT - 6 weeks ago

3 Healthcare Stocks to Buy Hand Over Fist in October

ISRG MRK


shalombt
shalombt Dec. 8 at 12:25 PM
$COST $JNJ $MA $JPM This is true for you too.
0 · Reply
seeitmarket
seeitmarket Dec. 8 at 7:27 AM
0 · Reply
andrewnyquist
andrewnyquist Dec. 8 at 6:15 AM
$JNJ Johnson & Johnson nearning important trend support area. It held the last 2 times. Will same pattern hold now? #IBDpartner @MarketSurge @InvestorsBusinessDaily
0 · Reply
RogerBarfield374
RogerBarfield374 Dec. 8 at 1:12 AM
💉 $JNJ CARVYKTI JUST TURNED MULTIPLE MYELOMA INTO A 30-MONTH VACATION One infusion and 80% of relapsed patients are still chilling treatment-free at 2.5 years—because apparently cancer didn’t get the memo that $JNJ rewrote the script. ⚡️ $JNJ drops updated Phase 3 bombshell: CARVYKTI keeps 80% of standard-risk patients progression-free for 30 months ⚡️ Works as early as second-line, single shot, no chemo, just vibes ⚡️ Already treated 9,000+ patients globally, real-world data backing the lab flex ⚡️ Earlier treatment = stronger immune comeback = longer cancer naps ⚡️ Big Pharma quietly turning “incurable” blood cancer into a manageable Tuesday
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 7 at 11:12 PM
Enter: $JNJ Calls Strike Price: $205 Expiry Date: JAN 02 2026 Buy in Price: $2.63 - $2.71 Sell Price: $4.39 Profit : +62% (Turn every $1 into $1.62) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
TalkMarkets
TalkMarkets Dec. 7 at 7:41 PM
Best #Dividend #Stocks For The #LongTerm - Sunday, Dec. 7 $CVX $JNJ $KO $MRK $O https://talkmarkets.com/content/real-estate--reits/best-dividend-stocks-for-the-long-term-sunday-dec-7?post=543058&userid=123969
0 · Reply
IrishFlyGirlQueenforever
IrishFlyGirlQueenforever Dec. 7 at 5:56 PM
$JNJ SLS Ven+aza has improved AML treatment by targeting BCL-2-dependent leukemic stem cells, but the prognosis is poor AML being heterogeneous and adaptable. Tho Ven can eliminate large portion of leukemic stem cells, others survive by relying on alternative anti-apoptotic proteins such as MCL-1 or BCL-XL, or by shifting their metabolic pathways. The bone marrow also provides protective shield on resistant cells. These surviving cells drive relapse, and resistance mechanisms limit long-term efficacy. GPS takes a different approach by activating the immune system to recognize and destroy cells expressing WT1 = leukemic stem cells. strategy is less vulnerable to the variability that undermines ven+aza. GPS induces immunologic memory, enabling long-term surveillance, reducing relapse risk. Unlike old regimens, GPS is used continuously maintaining immune pressure. GPS is disease-modifying rather than a temporary debulking therapy, offering a more durable solution to AML’s complexity
0 · Reply
USAStockmarket
USAStockmarket Dec. 7 at 2:59 PM
$LLY Eli Lilly $LLY, Pfizer $PFE and Johnson & Johnson $JNJ all secured spots on China’s 🇨🇳 first innovative drug catalog, which includes 19 medicines for conditions such as cancer and Alzheimer’s - Bloomberg
0 · Reply
TheUnmaker
TheUnmaker Dec. 7 at 4:31 AM
$BB $ISRG $JNJ $MDT https://blogs.blackberry.com/en/2024/01/revolutionizing-surgical-robotics-to-improve-patient-outcomes#:~:text=BlackBerry%C2%AE%20QNX%C2%AE%20is,with%20minimal%20impact%20on%20performance.
0 · Reply
TheUnmaker
TheUnmaker Dec. 7 at 4:19 AM
$BB $JNJ $MDT $ISRG https://www.surgicalroboticstechnology.com/company/qnx/
0 · Reply
BullRun4
BullRun4 Dec. 6 at 4:01 AM
$JNJ $CRDF Cardiff Oncology is expecting a strong Q1 catalyst with additional phase 2 mCRC data! 10X 💰💰💰💰💰💰💰💰💰💰💰💰💰💰💰
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 6 at 3:08 AM
Enter: $JNJ Calls Strike Price: $205 Expiry Date: DEC 26 2025 Buy in Price: $2.13 - $2.46 Sell Price: $3.86 Profit : +81% (Turn every $1 into $1.81) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 6 at 1:19 AM
Actionable Trade Alert for $JNJ: Market Context: $JNJ is currently trading at $202.48, showing strength but also signs of potential overbought conditions with an RSI of 70.6. The stock is above its 30-day MA of 196.0 and 50-day MA of 193.01, indicating a bullish trend. However, caution is warranted due to the high RSI. Directional Bias: Given the current price is near the 60D high of $207.81, there may be limited upside. The strong support is seen at the 30-day MA, while resistance is near the recent high. Trade Plan: - Suggested Entry: $202.50 - Stop Loss: $198.50 (approx. 2% below entry) - Take Profit Targets: 1. Target 1: $205.00 (1.23% ROI) 2. Target 2: $208.00 (2.47% ROI) 3. Target 3: $237.00 (17% ROI) Monitor the price action closely. If the stock reverses below the 30-day MA, consider exiting. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
Wenwenwenwenwenwen
Wenwenwenwenwenwen Dec. 6 at 12:42 AM
$JNJ out at 201.75 for now… will reenter around the 52 week lows
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Dec. 5 at 10:47 PM
0 · Reply
VR_CMT
VR_CMT Dec. 5 at 6:54 PM
$JNJ Johnson & Johnson nearing its 21 EMA from which a pullback buy opportunity could trigger in the next few sessions. Strong and steady buy pressure + RS in the stock suggest the uptrend will continue. $XLV
0 · Reply
dudebob
dudebob Dec. 5 at 5:57 PM
Quick ai summary: $KODK just cleaned up its balance sheet — pension-reversion unlocked ~$500–600M, debt mostly wiped out, cash flow + margins improving in Q3. Plus CEO on Fox talking about pivoting hard into pharma APIs + cGMP drug manufacturing and reviving battery-coating & EV-battery biz — leveraging in-house US manufacturing at Eastman Business Park. If they can execute, KODK could be multi-angle play: balance-sheet rescue + growth in pharma, batteries, EV supply chain, domestic manufacturing 🇺🇸 🏭 Might want to compare with other big players: $JNJ $TSLA $PFE $BLDP
0 · Reply
Fingerlickengood
Fingerlickengood Dec. 5 at 5:29 PM
$CDXS $JNJ $PFE $MRK This is pretty interesting! Patent date Nov 25, 2025. "FIELD OF THE INVENTION The present invention provides engineered penicillin G acylase (PGA) enzymes, polynucleotides encoding the enzymes, compositions comprising the enzymes, and methods of using the engineered PGA enzymes. PGA is one of the most used enzymes globally due to the massive market for beta-lactam antibiotics, with annual consumption estimated in the millions of tons." https://patents.justia.com/patent/12480111
2 · Reply
SparkyReturns
SparkyReturns Dec. 5 at 3:26 PM
$ICU Its unbelievable that the street hasn't picked up on this opportunity. * ICU * What other company has a market cap of only $12 Million but is launching a product with an annual market in the 10s of BILLIONS? [Read that again - 1000x] Patients' lives are saved and eliminates $100K/ year of dialysis dependency; Device has broad application for over a half dozen critical conditions (kidney, heart, ARDS, Sepsis, Covid, burns, etc); The device "sells itself" by saving hospitals $40K per average stay; Insurers will love it because their costs will go down; Government will love it to reduce number of Medicare patients on lifetime dialysis; FDA seems to be fast tracking all decisions, already gave grants; ZERO DEBT, and revenue ramping up. This may be the best time to get in for those looking for an investing idea. $TSLA $NVDA $JNJ $AMGN
2 · Reply
ConnieSweet455
ConnieSweet455 Dec. 5 at 3:10 PM
$JNJ remains a global healthcare and pharmaceuticals giant with stable earnings and strong R&D pipelines. AERT’s automation-driven delivery could support large regulated industries requiring controlled data environments. https://www.nasdaq.com/press-release/aeries-technologys-consulting-led-automation-practice-delivers-measurable-impact-0
0 · Reply
EthelBurkhardt272
EthelBurkhardt272 Dec. 5 at 3:00 PM
Johnson & Johnson still a textbook defensive compounder - recent buy signals and valuation chatter make $JNJ a solid anchor in choppy markets
0 · Reply
JarvisFlow
JarvisFlow Dec. 5 at 1:57 PM
Guggenheim has updated their rating for Johnson & Johnson ( $JNJ ) to Buy with a price target of 227.
0 · Reply